A Single-arm, Open-label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Endostar Subcutaneous Injection in Chinese Advanced NSCLC Patients
Latest Information Update: 05 Dec 2017
Price :
$35 *
At a glance
- Drugs Endostatin (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Jiangsu Simcere Pharmaceutical
- 05 Dec 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified jan 2016).
- 27 Jan 2016 New trial record